微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | 32.22% | -5.3% | -1.75% | 109/157 | 50.55% | 泽璟制药 | 94.64% | 行业排名> |
| 2025-12-31 | 32.79% | -7.52% | -5.18% | 109/157 | 50.61% | 海创药业 | 99.82% | 行业排名> |
| 2025-09-30 | 34.58% | -7.67% | 0.51% | 104/157 | -2.2% | 海创药业 | 98.62% | 行业排名> |
| 2025-06-30 | 34.41% | -10.41% | 1.14% | 107/157 | 14.83% | 海创药业 | 99.57% | 行业排名> |
| 2025-03-31 | 34.02% | -14.32% | -4.06% | 105/157 | 31.96% | 海创药业 | 99.52% | 行业排名> |
| 2024-12-31 | 35.46% | -18.12% | -5.34% | 106/157 | 51.88% | 艾力斯 | 96.74% | 行业排名> |
| 2024-09-30 | 37.46% | -15.57% | -2.47% | 102/157 | 22.51% | 首药控股 | 98.96% | 行业排名> |
| 2024-06-30 | 38.41% | -15.43% | -3.27% | 101/157 | 33.12% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-03-31 | 39.7% | -9.83% | -8.31% | 94/157 | 51.76% | 百利天恒 | 97.99% | 行业排名> |
| 2023-12-31 | 43.3% | 4.38% | -2.39% | 97/157 | 51.61% | 百利天恒 | 98.92% | 行业排名> |
| 2023-09-30 | 44.36% | -1.86% | -2.32% | 93/157 | 32.47% | 迈威生物 | 98.93% | 行业排名> |
| 2023-06-30 | 45.41% | 1.03% | 3.14% | 91/157 | 38.42% | 迈威生物 | 99.59% | 行业排名> |
| 2023-03-31 | 44.03% | -1.05% | 6.14% | 91/157 | 52.97% | 迈威生物 | 99.8% | 行业排名> |
| 2022-12-31 | 41.48% | -8.96% | -8.23% | 99/157 | 53.83% | 迈威生物 | 99.46% | 行业排名> |
| 2022-09-30 | 45.2% | -4.92% | 0.56% | 86/157 | 5.64% | 迈威生物 | 99.75% | 行业排名> |
| 2022-06-30 | 44.95% | -8.58% | 1.01% | 89/157 | 20.99% | 迈威生物 | 99.67% | 行业排名> |
| 2022-03-31 | 44.5% | -7.94% | -2.34% | 83/157 | 54.39% | 迈威生物 | 99.44% | 行业排名> |
| 2021-12-31 | 45.56% | -0.52% | -4.16% | 89/157 | 55.2% | 迈威生物 | 98.57% | 行业排名> |
| 2021-09-30 | 47.54% | -0.47% | -3.31% | 78/157 | 46.77% | 首药控股 | 99.93% | 行业排名> |
| 2021-06-30 | 49.17% | 1.74% | 1.72% | 80/157 | 47.23% | 艾力斯 | 99.41% | 行业排名> |
| 2021-03-31 | 48.34% | -4.85% | 5.55% | 71/157 | 54.13% | 艾力斯 | 98.7% | 行业排名> |
| 2020-12-31 | 45.8% | 10.08% | -4.12% | 91/157 | -148.64% | 艾力斯 | 99.4% | 行业排名> |
| 2020-09-30 | 47.77% | 18.59% | -1.16% | 74/157 | 56.43% | 首药控股 | 99.94% | 行业排名> |
| 2020-06-30 | 48.33% | 35.28% | -4.87% | 77/157 | 54.17% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-03-31 | 50.8% | 62.06% | 22.11% | 62/157 | 55.17% | 微芯生物 | 95.14% | 行业排名> |
| 2019-12-31 | 41.6% | -23.8% | 3.3% | 93/157 | -1242.15% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-09-30 | 40.28% | -28.8% | 12.75% | 75/157 | 55.23% | 微芯生物 | 95.81% | 行业排名> |
| 2019-06-30 | 35.72% | -33.62% | 13.96% | 88/157 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-03-31 | 31.35% | -38.97% | -42.59% | 91/157 | 51.07% | 微芯生物 | 96.11% | 行业排名> |
| 2018-12-31 | 54.6% | 25.23% | -3.47% | 65/157 | -211.97% | 微芯生物 | 95.5% | 行业排名> |
| 2018-09-30 | 56.57% | 32.8% | 5.1% | 49/157 | 54.14% | 微芯生物 | 96.27% | 行业排名> |
| 2018-06-30 | 53.82% | 33.23% | 4.77% | 52/157 | 53.53% | 贝达药业 | 95.47% | 行业排名> |
| 2018-03-31 | 51.37% | 36.75% | 17.81% | 54/157 | 54.16% | 贝达药业 | 95.51% | 行业排名> |
| 2017-12-31 | 43.6% | 24.19% | 2.37% | 72/157 | 52.55% | 贝达药业 | 95.54% | 行业排名> |
| 2017-09-30 | 42.59% | 23.79% | 5.44% | 54/157 | 49.09% | 贝达药业 | 95.74% | 行业排名> |
| 2017-06-30 | 40.39% | 14.76% | 7.54% | 60/157 | 47.91% | 退市金泰 | 96.19% | 行业排名> |
| 2017-03-31 | 37.56% | 19.16% | 6.99% | 57/157 | 46.94% | 贝达药业 | 95.81% | 行业排名> |
| 2016-12-31 | 35.11% | 17.96% | 2.04% | 77/157 | 48.46% | 退市金泰 | 95.93% | 行业排名> |
| 2016-09-30 | 34.41% | 13.37% | -2.25% | 56/157 | 46.19% | 贝达药业 | 95.58% | 行业排名> |
| 2016-06-30 | 35.2% | 23.16% | 11.65% | 61/157 | 46.26% | 贝达药业 | 95.89% | 行业排名> |
| 2016-03-31 | 31.52% | 26.21% | 5.91% | 56/157 | 43.86% | 微芯生物 | 97.46% | 行业排名> |